1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Adult Malignant Glioma Global Clinical Trials Review, H1, 2014

Adult Malignant Glioma Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Adult Malignant Glioma Global Clinical Trials Review, H1, 2014" provides data on the Adult Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Adult Malignant Glioma . It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Adult Malignant Glioma . This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Adult Malignant Glioma Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Adult Malignant Glioma 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Clinical Trials by G7 Countries: Proportion of Adult Malignant Glioma to Oncology Clinical Trials 12
Clinical Trials by Phase in G7 Countries 13
Clinical Trials in G7 Countries by Trial Status 14
Clinical Trials by Phase 15
In Progress Trials by Phase 16
Clinical Trials by Trial Status 17
Subjects Recruited Over a Period of Time 18
Clinical Trials by Sponsor Type 19
Prominent Sponsors 20
Top Companies Participating in Adult Malignant Glioma Therapeutics Clinical Trials 21
Prominent Drugs 22
Clinical Trial Profiles 23
Clinical Trial Overview of Top Companies 23
Insys Therapeutics, Inc. 23
Clinical Trial Overview of Insys Therapeutics, Inc. 23
Eli Lilly and Company 24
Clinical Trial Overview of Eli Lilly and Company 24
Sigma-Tau S.p.A. 25
Clinical Trial Overview of Sigma-Tau S.p.A. 25
Sanofi 26
Clinical Trial Overview of Sanofi 26
Merck and Co., Inc. 27
Clinical Trial Overview of Merck and Co., Inc. 27
GlaxoSmithKline plc 28
Clinical Trial Overview of GlaxoSmithKline plc 28
Amgen Inc. 29
Clinical Trial Overview of Amgen Inc. 29
Clinical Trial Overview of Top Institutes / Government 30
National Cancer Institute 30
Clinical Trial Overview of National Cancer Institute 30
Duke University 31
Clinical Trial Overview of Duke University 31
Shinshu University 32
Clinical Trial Overview of Shinshu University 32
Istituti Fisioterapici Ospitalieri 33
Clinical Trial Overview of Istituti Fisioterapici Ospitalieri 33
Tohoku University 34
Clinical Trial Overview of Tohoku University 34
Medical Research Council 35
Clinical Trial Overview of Medical Research Council 35
Osaka University 36
Clinical Trial Overview of Osaka University 36
Memorial Sloan Kettering Cancer Center 37
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 37
Emory University 38
Clinical Trial Overview of Emory University 38
Five Key Clinical Profiles 39
Appendix 90
Abbreviations 90
Definitions 90
Research Methodology 91
Secondary Research 91
About GlobalData 92
Contact Us 92
Disclaimer 92
Source 93

List of Tables
Adult Malignant Glioma Therapeutics, Global, Clinical Trials by Region, 2014* 6
Adult Malignant Glioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Adult Malignant Glioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Adult Malignant Glioma Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Adult Malignant Glioma Therapeutics Clinical Trials, Europe, Top Countries, 2014* 10
Adult Malignant Glioma Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Proportion of Adult Malignant Glioma to Oncology Clinical Trials, G7 Countries (%), 2014* 12
Adult Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 13
Adult Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 14
Adult Malignant Glioma Therapeutics, Global, Clinical Trials by Phase, 2014* 15
Adult Malignant Glioma Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 16
Adult Malignant Glioma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 17
Adult Malignant Glioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 18
Adult Malignant Glioma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 19
Adult Malignant Glioma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 20
Adult Malignant Glioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 21
Adult Malignant Glioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 22
Adult Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Insys Therapeutics, Inc., 2014* 23
Adult Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 24
Adult Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Sigma-Tau S.p.A., 2014* 25
Adult Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 26
Adult Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 27
Adult Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 28
Adult Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 29
Adult Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 30
Adult Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014* 31
Adult Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Shinshu University, 2014* 32
Adult Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Istituti Fisioterapici Ospitalieri, 2014* 33
Adult Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Tohoku University, 2014* 34
Adult Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical Research Council, 2014* 35
Adult Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Osaka University, 2014* 36
Adult Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 37
Adult Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Emory University, 2014* 38

List of Figures
Adult Malignant Glioma Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Adult Malignant Glioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Adult Malignant Glioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Adult Malignant Glioma Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 9
Adult Malignant Glioma Therapeutics Clinical Trials, Europe, Top Countries (%), 2014* 10
Proportion of Adult Malignant Glioma to Oncology Clinical Trials, G7 Countries (%), 2014* 12
Adult Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 13
Adult Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 14
Adult Malignant Glioma Therapeutics, Global, Clinical Trials by Phase (%), 2014* 15
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 16
Adult Malignant Glioma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 17
Adult Malignant Glioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 18
Adult Malignant Glioma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 19
Adult Malignant Glioma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 20
Adult Malignant Glioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 21
Adult Malignant Glioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 22
GlobalData Methodology 91

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025 Summary Myelofibrosis (MF) is a rare blood disorder, which is characterized by bone marrow fibrosis. Currently, there is ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.